Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Carfilzomib for the treatment of multiple myeloma.

Lue J, Goel S, Mazumder A.

Drugs Today (Barc). 2013 Mar;49(3):171-9. doi: 10.1358/dot.2013.49.3.1939264.

PMID:
23527321
2.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ.

Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.

3.

Carfilzomib: a novel second-generation proteasome inhibitor.

Khan ML, Stewart AK.

Future Oncol. 2011 May;7(5):607-12. doi: 10.2217/fon.11.42.

4.

Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.

Thompson JL.

Ann Pharmacother. 2013 Jan;47(1):56-62. doi: 10.1345/aph.1R561. Epub 2013 Jan 8. Review.

PMID:
23300152
5.

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M.

Br J Haematol. 2012 Sep;158(6):739-48. doi: 10.1111/j.1365-2141.2012.09232.x. Epub 2012 Jul 30.

6.

Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.

McBride A, Klaus JO, Stockerl-Goldstein K.

Am J Health Syst Pharm. 2015 Mar 1;72(5):353-60. doi: 10.2146/ajhp130281. Review.

PMID:
25694410
7.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS.

Blood. 2012 Jun 14;119(24):5661-70. doi: 10.1182/blood-2012-03-414359. Epub 2012 May 3.

8.

Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.

Hobeika L, Self SE, Velez JC.

BMC Nephrol. 2014 Sep 30;15:156. doi: 10.1186/1471-2369-15-156.

9.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):310-8. doi: 10.1016/j.clml.2012.08.003.

PMID:
23040437
10.
11.

Role of carfilzomib in the treatment of multiple myeloma.

Khan RZ, Badros A.

Expert Rev Hematol. 2012 Aug;5(4):361-72.

PMID:
22992230
12.

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.

Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink PP, de Bruin G, Kisselev AF, Overkleeft H, Driessen C.

Cancer Chemother Pharmacol. 2015 Aug;76(2):383-96. doi: 10.1007/s00280-015-2801-0. Epub 2015 Jun 23.

13.

Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.

Steele JM.

J Oncol Pharm Pract. 2013 Dec;19(4):348-54. doi: 10.1177/1078155212470388. Epub 2013 Jan 4. Review.

PMID:
23292972
14.

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.

Kraus M, Bader J, Geurink PP, Weyburne ES, Mirabella AC, Silzle T, Shabaneh TB, van der Linden WA, de Bruin G, Haile SR, van Rooden E, Appenzeller C, Li N, Kisselev AF, Overkleeft H, Driessen C.

Haematologica. 2015 Oct;100(10):1350-60. doi: 10.3324/haematol.2014.109421. Epub 2015 Jun 11.

15.

Safety of proteasome inhibitors for treatment of multiple myeloma.

Schlafer D, Shah KS, Panjic EH, Lonial S.

Expert Opin Drug Saf. 2017 Feb;16(2):167-183. doi: 10.1080/14740338.2017.1259310. Epub 2016 Nov 28. Review.

PMID:
27841029
16.

Carfilzomib (Kryprolis) for multiple myeloma.

[No authors listed]

Med Lett Drugs Ther. 2012 Dec 24;54(1406):103-4. Review. No abstract available.

PMID:
23282792
17.

Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.

Highsmith KN, Chen SE, Horowitz S.

Pharmacotherapy. 2014 Sep;34(9):927-40. doi: 10.1002/phar.1463. Epub 2014 Jul 19. Review.

PMID:
25044413
18.

Carfilzomib: a novel agent for multiple myeloma.

Redic K.

J Pharm Pharmacol. 2013 Aug;65(8):1095-106. doi: 10.1111/jphp.12072. Epub 2013 Apr 24. Review.

19.

Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.

Vij R.

Oncology (Williston Park). 2011 Nov 15;25 Suppl 2:45-55. Review.

20.

Bortezomib in multiple myeloma.

Mateos MV, San Miguel JF.

Best Pract Res Clin Haematol. 2007 Dec;20(4):701-15. Review.

PMID:
18070714

Supplemental Content

Support Center